Adaptimmune Therapeutics plc
Other OTCTotal Valuation
Adaptimmune Therapeutics plc carries a market capitalization of 6.63M, placing it among publicly traded companies globally. Its enterprise value stands at 84.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.63M |
| Enterprise Value | 84.69M |
Share Statistics
Adaptimmune Therapeutics plc currently has 1.59B shares outstanding.
| Shares Outstanding | 1.59B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.95, and the price-to-book ratio stands at -0.05.
| PE Ratio | N/A |
| PS Ratio | 0.95 |
| PB Ratio | -0.05 |
| P/TBV Ratio | -0.83 |
| P/FCF Ratio | -0.33 |
| P/OCF Ratio | -0.33 |
Enterprise Valuation
| EV / Sales | 1.30 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Adaptimmune Therapeutics plc maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -68.60, indicating conservative leverage, while an interest coverage ratio of -23.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.52 |
| Quick Ratio | 1.07 |
| Debt / Equity | -68.60 |
| Debt / EBITDA | -0.36 |
| Interest Coverage | -23.83 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -75.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.59 |
Taxes
| Income Tax | 3.71M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Adaptimmune Therapeutics plc's stock has declined approximately -89.63086% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -89.63086% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Adaptimmune Therapeutics plc generated 65.09M in revenue and converted that into -169.76M in net income, yielding earnings per share of -0.66. EBITDA reached -135.01M, while operating income came in at -145.64M.
| Revenue | 65.09M |
| Gross Profit | 17.58M |
| Operating Income | -145.64M |
| Pretax Income | -166.04M |
| Net Income | -169.76M |
| EBITDA | -135.01M |
| EBIT | -145.64M |
| Earnings Per Share (EPS) | -0.66 |
Balance Sheet
Adaptimmune Therapeutics plc holds 26.06M in cash and equivalents against 48.68M in total debt, resulting in a net debt position of -386,000.00. Total book value stands at -1.17B, with working capital of 26.60M providing operational flexibility.
| Cash & Cash Equivalents | 26.06M |
| Total Debt | 48.68M |
| Net Debt | -386,000.00 |
| Equity (Book Value) | -1.17B |
| Book Value Per Share | -4.52 |
| Working Capital | 26.60M |
Cash Flow
Adaptimmune Therapeutics plc produced -190.03M in operating cash flow over the past twelve months. After subtracting -2.89M in capital expenditures, free cash flow totaled -192.91M - equivalent to -0.74 per share.
| Operating Cash Flow | -190.03M |
| Capital Expenditures | -2.89M |
| Free Cash Flow | -192.91M |
| FCF Per Share | -0.74 |
Margins
Adaptimmune Therapeutics plc operates with a gross margin of 94.81, reflecting its pricing power and cost economics. The operating margin of -223.76 and net profit margin of -260.82 provide insight into operational efficiency.
| Gross Margin | 94.81 |
| Operating Margin | -223.76 |
| Pretax Margin | -255.12 |
| Profit Margin | -260.82 |
| EBITDA Margin | -207.43 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.15 |
| FCF Yield | -301.49 |
Scores
Adaptimmune Therapeutics plc posts an Altman Z-Score of -15.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -15.78 |